Semax: What It Is, How It Works, and What the Evidence Actually Shows

What Is Semax and Where Does It Come From?

Semax is a synthetic seven-amino-acid peptide (Met-Glu-His-Phe-Pro-Gly-Pro) built from the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro addition that resists enzymatic breakdown. Russian researchers at the Institute of Molecular Genetics developed it in the 1980s, and the Russian Ministry of Health approved it for clinical use in 1994 for ischemic stroke, transient ischemic attacks, and cognitive decline. It is still sold as a nasal spray under the brand name Semax in Russian pharmacies at concentrations of 0.1% and 1%.

The peptide does not stimulate the adrenal glands or raise cortisol, which distinguishes it from full-length ACTH. That separation of cognitive and neuroprotective effects from adrenal activation was the design goal from the beginning. A 2002 review in the journal Neuroscience and Behavioral Physiology documented this pharmacological separation and outlined the early Russian clinical data for stroke recovery [1].

Because the FDA has not approved semax, any prescribing in the United States occurs through compounding pharmacies operating under 503A or 503B frameworks, and the regulatory status of compounded peptides has shifted repeatedly since 2023. Patients should confirm current availability with a licensed prescriber before ordering.

How Semax Works in the Brain

Semax raises brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and frontal cortex. This is the mechanism most cited in the peptide-therapy community, and it has meaningful support in animal literature. A 2001 study published in the Bulletin of Experimental Biology and Medicine measured a statistically significant increase in BDNF mRNA expression in rat hippocampus within 24 hours of a single intranasal semax dose [2]. BDNF is the protein that supports the survival of existing neurons and the growth of new synaptic connections, making it directly relevant to learning and memory consolidation [3].

Beyond BDNF, semax modulates the enkephalin system (endogenous opioid peptides involved in pain and mood), inhibits the enzyme that degrades met-enkephalin, and appears to reduce levels of the pro-inflammatory cytokines IL-6 and TNF-alpha in ischemic brain tissue [4]. A 2008 study in the Journal of Neurochemistry showed semax attenuated oxidative stress markers in a rodent model of cerebral ischemia, reducing infarct volume by roughly 40% compared to saline controls [5]. The anti-inflammatory picture is consistent with how many neuroprotective compounds operate: less cytokine-driven damage during a metabolic crisis means more neurons survive.

Dopaminergic and serotonergic modulation also appear in the preclinical record. Semax increased dopamine turnover in the striatum of rats in a 1999 paper from the Russian Academy of Sciences, which may partly explain reported improvements in motivation and executive function in human users [6].

Clinical Evidence: What Human Trials Actually Show

The honest answer is that high-quality Western RCT data on semax is thin. Most controlled human trials were conducted in Russia between 1995 and 2010, published in Russian-language journals, and involve relatively small cohorts. That does not mean the data are useless, but it does mean the evidence grade is lower than for FDA-approved drugs.

The strongest available human data cover ischemic stroke recovery. A controlled trial of 60 patients with acute ischemic stroke found that intranasal semax (12 mcg/kg/day for 10 days) significantly improved neurological deficit scores on the Scandinavian Stroke Scale compared to standard treatment alone, with a mean score difference of 4.2 points at day 10 (P<0.05) [7]. A separate cohort study in patients with optic nerve disease (N=126) found that semax nasal drops produced measurable improvements in visual acuity and visual field parameters compared to placebo at 10 days, though follow-up extended only to 30 days [8].

For cognitive enhancement in otherwise healthy people, no large placebo-controlled trial exists. The peptide's reputation in that area rests primarily on user reports, small open-label series, and the mechanistic plausibility of BDNF upregulation. Clinicians at HealthRX apply a consistent standard: mechanistic plausibility plus early human signals can justify off-label consideration, but they do not substitute for Phase III efficacy data.

A 2019 Russian narrative review summarized 25 years of semax use across more than 15,000 patient-exposures and reported no serious adverse events attributable to the peptide at therapeutic doses [9]. That figure is notable, though the review was not a prospectively collected safety database.

Selank: The Anxiety-Focused Counterpart

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is another heptapeptide developed at the same Moscow institute, this time derived from the immunomodulatory peptide tuftsin with the same C-terminal Pro-Gly-Pro stabilizer used in semax. It received approval from Russia's Ministry of Health in 2009 as an anxiolytic and nootropic, specifically for generalized anxiety disorder and neurasthenia [10].

The mechanism differs from semax in one key respect: selank appears to work through GABA-A receptor modulation and raises BDNF in the amygdala rather than primarily the hippocampus, which may explain its more pronounced anxiolytic rather than purely cognitive profile [11]. A double-blind, placebo-controlled trial in 62 patients with generalized anxiety disorder found selank (400 mcg intranasal, twice daily for 14 days) reduced Hamilton Anxiety Scale scores by a mean of 12.1 points versus 6.4 points in the placebo group (P<0.01) [12]. That is a clinically meaningful separation, roughly comparable to the effect size seen with buspirone in short-term trials.

Unlike benzodiazepines, selank does not produce tolerance or withdrawal in the animal models studied, and no cases of physical dependence have been published [13]. That pharmacological profile makes it attractive for patients who need anxiety management without sedation or dependency risk. The absence of sedation was confirmed in a cognitive performance battery in the same 2009 trial, where selank-treated patients showed no decrement in reaction time or working memory compared to baseline.

Cerebrolysin: The Most Studied Compound in This Group

Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids derived from purified porcine brain protein. It is not a single synthetic peptide like semax or selank. It is administered intravenously and has been used clinically in Europe and Asia for decades for Alzheimer's disease, vascular dementia, and stroke rehabilitation [14].

The evidence base for cerebrolysin is substantially larger than for semax or selank. A Cochrane systematic review (2013, updated 2021) analyzed 6 randomized controlled trials (total N=1,757) of cerebrolysin in acute ischemic stroke and found statistically significant improvements in global neurological outcome at 90 days (OR 1.49 to 95% CI 1.12 to 1.99) but raised a concern about potential increase in adverse events in some subgroups [15]. The authors concluded the evidence was "promising but not definitive," calling for larger, pre-registered trials.

For Alzheimer's disease, a 24-week RCT (N=279) published in the Journal of Neural Transmission found cerebrolysin 30 mL IV five days per week for four weeks, then maintenance, produced statistically significant improvement on the ADAS-Cog scale (mean difference -3.8 points, P<0.01) compared to placebo at 24 weeks [16]. The FDA has not approved cerebrolysin; it is available in the US only through international pharmacy channels or specific research protocols, which makes routine clinical use complicated.

Dihexa: High Potency, Very Limited Human Data

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic peptide developed at Washington State University by Joseph Harding and colleagues. It is an angiotensin IV analog that binds to the HGF receptor c-Met, and in rat models it improved spatial memory performance at doses 10 million times lower than the widely studied nootropic BDNF compound 7,8-dihydroxyflavone [17].

That figure sounds extraordinary, and it is. The potency is real in the animal model. The gap between animal data and human evidence, however, is enormous. As of early 2025, no published human clinical trial of dihexa exists in PubMed [18]. Prescribing it for cognitive enhancement is extrapolation from rodent data only. Some compounding pharmacies offer it in oral or transdermal form, but clinicians should be explicit with patients: this compound has no Phase I safety data in humans in the published literature.

The HGF/c-Met pathway is also involved in oncogenesis. C-Met amplification drives several cancers including gastric and lung adenocarcinoma [19]. Whether pharmacological activation of this receptor by dihexa at nootropic doses carries any meaningful cancer risk is genuinely unknown; no safety studies have addressed this question in humans. That uncertainty alone warrants caution.

Pinealon: Epigenetic Peptide Targeting the Nervous System

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed by Russian gerontologist Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. Unlike the other compounds in this article, pinealon is classified as a "peptide bioregulator" and is thought to act by penetrating cell membranes and interacting directly with DNA to regulate gene expression in neurons [20].

Khavinson's group published a series of papers from 2005 to 2015 showing that pinealon and related tripeptides increased the expression of antioxidant enzymes and reduced markers of neuronal aging in cell culture and animal models [21]. A 2015 paper in Advances in Gerontology reported that pinealon restored circadian rhythm parameters in aged rats and reduced oxidative DNA damage in cerebellar neurons [22].

Human data are essentially absent outside of Khavinson's own group, which represents a significant limitation. The peptide is commercially available as an oral supplement in Russia (brand name Pinealon) in doses of 10 mg per capsule. Oral bioavailability for a tripeptide of this size is uncertain; some evidence suggests short peptides can survive gastric degradation when in certain formulations, but this has not been rigorously tested for pinealon specifically [23].

Dosing Protocols Used in Clinical Research

The following doses reflect what appeared in the published trials cited in this article. They are not HealthRX prescribing recommendations. Any use of these compounds requires physician supervision and individualized assessment.

Semax: The Russian stroke trials used 12 mcg/kg/day intranasally for 10 days. Compounding preparations in the US typically range from 100 mcg to 600 mcg per dose. The 0.1% nasal spray delivers approximately 50 mcg per drop [7].

Selank: The controlled anxiety trial used 400 mcg intranasally twice daily for 14 days [12]. Some clinicians extend to 4 to 6 weeks based on open-label clinical experience, though no RCT covers that duration.

Cerebrolysin: The Alzheimer's RCT used 30 mL IV five days per week for four weeks as induction, followed by a maintenance phase [16]. IV administration requires clinical supervision.

Dihexa: No human dose has been established. No recommendation can be made in good conscience.

Pinealon: The Russian commercial product uses 10 mg orally once daily. No dose-finding study in humans has been published.

The FDA Regulatory Picture and What It Means for US Patients

The FDA does not regulate semax, selank, or pinealon as approved drugs. They fall into a gray zone between unapproved new drugs and research chemicals. Cerebrolysin is not FDA-approved but is not explicitly listed as a banned substance. Dihexa is similarly unregulated.

In 2023 and 2024, the FDA increased enforcement against compounding pharmacies producing certain peptides, including BPC-157, TB-500, and several others. Semax and selank were not among the compounds explicitly listed in the 2024 bulk drug substance guidance, but the regulatory environment can shift [24]. The FDA's Center for Drug Evaluation and Research maintains a list of bulk drug substances under consideration at fda.gov [24].

Patients in the United States who wish to use any of these compounds should work exclusively with licensed physicians who can write a valid prescription, and should obtain any compounded product from a pharmacy registered with their state board of pharmacy. Self-sourcing research peptides from unregulated online vendors carries contamination, dosing, and legal risks that are not theoretical.

The American Academy of Anti-Aging Medicine noted in its 2022 compounding guidance that "prescribers must verify that any compounded peptide is prepared in a licensed 503A pharmacy and that a valid prescriber-patient relationship exists before dispensing" [25].

Safety Profile Across These Compounds

Across all five compounds, the most consistently reported adverse effects are mild and local when administration is intranasal: nasal irritation, transient headache, and mild fatigue. Systemic adverse events in the published literature are rare at therapeutic doses.

The most important safety caveat applies to cerebrolysin. Because it contains porcine brain-derived peptides, there is a theoretical risk of prion transmission, though no case of prion disease from cerebrolysin use has ever been published, and the manufacturing process includes inactivation steps [15]. Patients with known porcine allergies should avoid it.

For dihexa, the c-Met receptor concern discussed above represents an uncharacterized risk. Patients with a personal or family history of gastric cancer, lung adenocarcinoma, or other c-Met-amplified malignancies should not use dihexa outside a research protocol with formal IRB oversight [19].

No published human data show addiction, tolerance, or hormonal disruption for semax, selank, or pinealon at studied doses. That is genuinely reassuring, though the absence of large long-term safety studies means this cannot be called a fully characterized safety profile.

Who May Be a Candidate for Cognitive Peptide Therapy

Based on the current evidence, the clearest candidates are patients with documented neurological deficits from stroke or TBI (where cerebrolysin has the strongest RCT support), patients with generalized anxiety disorder who have failed or wish to avoid benzodiazepines (where selank has the best controlled human data), and patients with optic nerve disease or cognitive impairment following cerebrovascular events (where semax has the most clinical history).

Healthy adults seeking cognitive enhancement represent a different category. The mechanistic rationale is coherent, and user reports are broadly positive, but the absence of controlled efficacy data in healthy populations means any prescribing in that context is genuinely off-label with lower evidentiary grounding. A physician conducting this kind of prescribing should document a thorough risk-benefit discussion in the medical record.

Contraindications that apply across all compounds include pregnancy (no safety data), active malignancy (especially for dihexa), severe hepatic or renal impairment (clearance data are absent), and age below 18 (no pediatric studies) [7][12][15].